MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2022 International Congress » Parkinson's Disease and Lewy Body Dementia

Meeting: 2022 International Congress

Capturing the complexity of patients with parkinsonism: Baseline characteristics of participants in the PRIME-UK cross-sectional study

E. Tenison, D. Pendry-Brazier, M. Smith, F. Lithander, Y. Ben-Shlomo, E. Henderson (Bristol, United Kingdom)

Characteristics and Techniques to Improve Micrographia in Parkinson’s Disease

S. Shahid (Southampton, USA)

Connectivity of dopaminergic networks in the continuum of Dementia with Lewy Bodies

A. Pilotto, S. Caminiti, E. Premi, A. Galli, E. Ferrari, G. Bonzi, S. Gipponi, E. Cottini, B. Paghera, D. Perani, A. Padovani (brescia, Italy)

Defining nomenclature and age cut off for Early Onset Parkinson’s Disease: Recommendations from the Early Onset Parkinson’s Disease Task Force.

R. Mehanna, K. Smilowska, A. Merola, B. Zhang, B. Post, C. Marras, J. Fleisher, K. Kumar, M. Salari, O. Ross, R. Alcalay, T. Hatano, V. Mcconvey, Y-R. Wu, E-K. Tan, R. Savica (Houston, USA)

Deleterious GRN mutations: a new player in the etiology of Lewy body dementia

P. Reho, S. Koga, Z. Shah, R. Chia, R. Rademakers, C. Dalgard, B. Boeve, T. Beach, D. Dickson, O. Ross, S. Scholz (Bethesda, USA)

Distinct amyloid-dependent patterns of nigral dopamine depletion in Lewy body diseases

K. Baik, J. Cha, M. Park, Y. Lee, SW. Kang, SH. Yoon, H. Na, Y. Sohn, P. Lee (Seoul, Republic of Korea)

Evaluation of Actigraphy-Based Circadian Rhythm and Motor Function Measures for Monitoring Treatment of Lewy Body Dementia in PRESENCE Study

X. Dang, J. Wang, C. Battioui, M. Williamson, J. Zou, A. Hake, H. Zhang, B. Winger, J. Yang, K. Biglan (Cambridge, USA)

Head injury prior to Parkinson’s disease predicts faster self-reported motor and cognitive decline

E. Brown, M. San Luciano, S. Goldman, M. Korell, B. Contreras, C. Tanner (San Francisco, USA)

Height and nigral neuron density in Parkinson’s disease

L. Saari, E. Backman, P. Wahlsten, M. Gardberg, V. Kaasinen (Turku, Finland)

in vivo and autopsy validation of alpha-synuclein seeding activity using RT-QuIC assay in the gastrointestinal tract of patients with Parkinson’s disease

C. Shin, JY. Han, YP. Choi, SI. Kim, SH. Park, HK. Yang, HJ. Lee, SH. Kong, YS. Suh, HJ. Kim, B. Jeon (Sejong-si, Republic of Korea)

Inflammatory biomarkers in newly diagnosed patients with Parkinson’s disease

C. Pedersen, A. Ushakova, G. Alves, O-B. Tysnes, D. Aarsland, J. Lange, J. Maple-Grødem (Sandnes, Norway)

Investigating genetic risk factors for Lewy body dementia

J. Lee, S. Jo, S. Lee, MS. Kim, SJ. Chung (Seoul, Republic of Korea)

Lewy body disease clinical subgroups present similar disease progression rates

C. Abdelnour, C. Young, E. Müller-Oehring, D. Ferreira, M. Shahid, M. Plastini, J. Winer, K. Poston (Stanford, USA)

Longitudinal Program to Prevent PD (LoPP-PD): Multimodal Risk Stratification Informs Personalized Intervention

K. Niotis, K. Akiyoshi, R. Isaacson, S. Isaacson (New York, USA)

Neuropsychological correlates of Cognitive fluctuations in dementia with Lewy bodies

N. Dudchenko, O. Levin (Moscow, Russian Federation)

Parkinson’s Progression Marker Initiative (PPMI) Online identifies people with features of prodromal Parkinson’s Disease through online questionnaires

E. Brown, L. Chahine, D. Alonso, C. Coffey, R. Dobkin, T. Foroud, M. Korell, A. Lorenzo, C. Marras, W. Poewe, T. Sherer, A. Siderowf, T. Simuni, E. Tolosa, J. Valverde Twiggs, D. Weintraub, S. Chowdhury, K. Marek, C. Tanner (San Francisco, USA)

Parkinson’s Progression Markers Initiative (PPMI) Online expands biomarker research in Parkinson’s disease (PD)

E. Brown, D. Alonso, L. Chahine, C. Coffey, R. Dobkin, M. Korell, A. Lorenzo, C. Marras, W. Poewe, T. Sherer, A. Siderowf, T. Simuni, E. Tolosa, J. Valverde Twiggs, D. Weintraub, S. Chowdhury, K. Marek, C. Tanner (San Francisco, USA)

Plasma p-tau181 is increased in Lewy body dementia and relates to cognitive performance

N. Hannaway, A. Heslegrave, R. Bhome, I. Dobreva, H. Zetterberg, R. Weil (LONDON, United Kingdom)

Postural Instability in Parkinson’s Disease: Phenotypic data from The Cincinnati Cohort Biomarker Program

K. Duque, J. Abanto, R. Bode, N. Gregor, F. Pariona, J. Hernandez, A. Espay, L. Marsili (Cincinnati, USA)

Predicting cognitive decline using neuropsychiatric symptoms in prodromal Lewy body disease.

L. Wright, P. Donaghy, D. Burn, J-P. Taylor, J. O'Brien, A. Yarnall, F. Matthews, M. Firbank, A. Thomas, R. Lawson (Newcastle upon Tyne, United Kingdom)

Sex Modulates Cognitive Association of Lewy Body Pathology

E. Bayram, K. Wang, A. Tsai, D. Coughlin, I. Litvan (La Jolla, USA)

Sleep stability, arousals and cycle structure in alfa-synucleinopathies: a comparative study between isolated REM sleep behaviour disorder (iRBD), Parkinson’s Disease (PD) and Dementia with Lewy Bodies (DLB)

M. Magriço, P. Bugalho (Lisboa, Portugal)

Smoking and Substantia Nigra Neuron Density in the Presence and Absence of Lewy Pathology

G. Ross, R. Abbott, H. Petrovitch, J. Duda, J. Uyehara-Lock, K. Masaki, C. Tanner (Honolulu, USA)

Survival and progression in GBA-associated dementia with Lewy bodies

T. Shiner, A. Mirelman, Y. Piura, A. Migirov Sandrovitz, L. Raif, S. Korenblum, O. Goldstein, G. Kave, M. Gana Weisz, A. Bar Shira, T. Gurevich, A. Orr-Urtreger, N. Giladi, N. Bregman (Tel Aviv, Israel)

The Unmet needs for advanced Parkinson Disease in -Patients’ during the Covid-19 pandemic in Israel

N. Simantov, A. Socher, T. Gurevich (Tel-Aviv, Israel)

Visual Hallucinations and Parkinson’s Disease Neuropathology among Decedents with and without Parkinson’s Disease or Lewy Body Dementia During Life

H. Petrovitch, R. Abbott, M. Barrett, K. Masaki, C. Tanner, J. Uyehara-Lock, W. Ross (Honolulu, USA)

Visualising cholinergic nerves in dementia with Lewy bodies using PET and FEOBV

N. Okkels, J. Horsager, A. Hansen, M. Damholdt, P. Kjeldsen, K. Vestergaard, K. Andersen, C. Skjærbæk, T. Fedorova, J. Mortensen, G. Bekan, H. Gottrup, P. Borghammer (Aarhus N, Denmark)

α-Synuclein molecular behavior and proteomic profiling distinguish subtypes of Lewy body disorders

I. Martinez-Valbuena, E. Swinkin, E. Santamaria Martinez, J. Fernandez-Irigoyen, V. Sackmann, A. Kim, P. Gonzalez-Latapi, G. Kuhlman, S. Bhowmick, NP. Visanji, AE. Lang, GG. Kovacs (Toronto, Canada)

« View all sessions from the 2022 International Congress.

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley